Theradiag SA
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more
Theradiag SA (ALTHE) - Total Liabilities
Latest total liabilities as of June 2025: €14.09 Million EUR
Based on the latest financial reports, Theradiag SA (ALTHE) has total liabilities worth €14.09 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Theradiag SA - Total Liabilities Trend (2001–2024)
This chart illustrates how Theradiag SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Theradiag SA Competitors by Total Liabilities
The table below lists competitors of Theradiag SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Auctus Alternative Investments Ltd
AU:AVC
|
Australia | AU$6.61 Million |
|
Global AI Inc
OTCQB:GLAI
|
USA | $4.25 Million |
|
Kingswood Holdings Limited
PINK:KWGHF
|
USA | $124.72 Million |
|
Elco Ltd
TA:ELCO
|
Israel | ILA21.90 Billion |
|
Austral Resources Australia Ltd
AU:AR1
|
Australia | AU$197.46 Million |
|
Sing Tao News Corporation Limited
PINK:STAOF
|
USA | $298.42 Million |
|
Harn Len Corporation Bhd
KLSE:7501
|
Malaysia | RM154.08 Million |
|
Rail Vision Ltd. Ordinary Share
NASDAQ:RVSN
|
USA | $2.68 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Theradiag SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theradiag SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theradiag SA (2001–2024)
The table below shows the annual total liabilities of Theradiag SA from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €11.47 Million | -11.86% |
| 2023-12-31 | €13.01 Million | -2.90% |
| 2022-12-31 | €13.40 Million | +2.26% |
| 2021-12-31 | €13.10 Million | -4.95% |
| 2020-12-31 | €13.78 Million | +30.13% |
| 2019-12-31 | €10.59 Million | +4.91% |
| 2018-12-31 | €10.10 Million | -1.96% |
| 2017-12-31 | €10.30 Million | +12.77% |
| 2016-12-31 | €9.13 Million | +7.44% |
| 2015-12-31 | €8.50 Million | +54.25% |
| 2014-12-31 | €5.51 Million | -18.33% |
| 2013-12-31 | €6.75 Million | +132.77% |
| 2012-12-31 | €2.90 Million | +32.55% |
| 2011-12-31 | €2.19 Million | -16.97% |
| 2010-12-31 | €2.63 Million | -28.70% |
| 2009-12-31 | €3.69 Million | +354.93% |
| 2001-12-31 | €812.00K | -- |